HOPX/LAGY Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-9462R-Cy5.5 |
| Product Name | HOPX/LAGY Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
IF
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human HOPX/LAGY |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 84525 |
| Swiss Prot | Q9BPY8 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | HOD; HOP; OB1; LAGY; TOTO; CAMEO; NECC1; SMAP31; Homeodomain-only protein; Lung cancer-associated Y protein; Not expressed in choriocarcinoma protein 1; Odd homeobox protein 1; HOPX |
| Background | Atypical homeodomain protein which does not bind DNA and is required to modulate cardiac growth and development. Acts via its interaction with SRF, thereby modulating the expression of SRF-dependent cardiac-specific genes and cardiac development. Prevents SRF-dependent transcription either by inhibiting SRF binding to DNA or by recruiting histone deacetylase (HDAC) proteins that prevent transcription by SRF. Overexpression causes cardiac hypertrophy (By similarity). May act as a tumor suppressor. |
| Application Dilution | |
| IF | WB1:300-5000 |